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Abstract: Krüppel-like factors (Klf) 4 and 5 belong to a family of zinc finger-containing transcription factors that share 
homology with the Drosophila gene Krüppel. They regulate proliferation and differentiation of a wide variety of cells and 
have been linked to tumorigenesis. Their most striking role so far has turned out to be their ability to reprogram/ maintain 
embryonic stem cell fate. In this review, the data available in the field regarding their role in proliferation and differentia-
tion and their coupling to carcinogenesis are summarized. The emphasis is on their context dependence and how they 
might be able to regulate diverse transcriptional outputs from the genome.  
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1. KRÜPPEL-LIKE FACTORS 
  Krüppel-like factors (KLFs) are zinc finger proteins that 
belong to the Sp1/Klf family of transcription factors. This 
family is characterised by a highly conserved C-terminal 
DNA-binding domain containing three zinc fingers which 
are similar to those found in the drosophila protein Krüppel. 
In drosophila, the amorphic mutation of Krüppel causes the 
lack of all three thoracic segments along with five of the 
eight abdominal segments. The missing abdominal segments 
are partially replaced by the mirror-image duplication of the 
normal posterior-abdominal segments [1]. This gives the 
embryo a crippled look, hence the name for the family. At 
least 17 Krüppel like factors belonging to this family, have 
so far been identified in mammals. These play diverse roles 
during differentiation and development [2-4].  
1.1. Klf4 and Klf5 
  Klf4 and Klf5 are two of the family members that often 
show overlapping as well as mutually exclusive expression 
patterns. For instance, Klf4 is expressed prominently in the 
differentiating compartment of the gut [5]. Klf5 expression 
on the other hand is associated with the crypts of intestinal 
villi, which are active sites of proliferation [6]. Similar to the 
pattern in the intestine, Klf4 is expressed in the differentiat-
ing cells of the epidermis [7] while Klf5 is enriched in the 
basal layer or the proliferating compartment of the epidermis 
[8]. A detailed comparison of the expression pattern of these 
genes reveals interesting temporal differences during devel-
opment. For instance, in the embryonic day 10.5 (E10.5) 
mouse embryo, Ohnishi et al. [8] did not detect any Klf4 
expression in the primitive gut, which instead had high level 
expression of Klf5. At E15.5, Klf4 and Klf5 transcripts were 
similarly abundant in the developing gut. As development 
progressed, at E17.5, Klf4 transcripts were nearly absent in 
the intestine while the Klf5 expression remained still high in 
the intestine. A temporal regulation of Klf5 during develop- 
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ment was also detected by Conkright et al. [6]. In this study 
high level expression of Klf5 was observed in E7 embryos, it 
was completely absent at day 11 and low levels of expres-
sion returned at day 15 and 17.  
  In the adult mice, Klf4 expression is high in the colon 
(proximal and distal) [5]. Moderate levels of transcript are 
also detected in the distal small intestine, testis and lung. In 
this study, no appreciable amount of message was detected 
in the brain, kidney, liver, spleen, thymus, heart, muscle and 
fat. Further, in situ hybridization showed that Klf4 was pri-
marily expressed from the middle to upper region of the 
colonic crypt epithelium, indicating that it is expressed in 
cells that are in the process of migrating from the base to-
wards the top of the crypt. Klf5 in the adult mice is predomi-
nantly expressed in the stomach, small intestine and colon. 
In addition lower levels of transcript are detected in the skin, 
lung, uterus, placenta and testis [6]. A comparison of the 
expression pattern in human and mice shows that in both 
these species, Klf5 is enriched in the small intestine and co-
lon [6, 9]. Although identical tissues were not represented on 
the Northern blots in the two studies, some differences be-
tween mouse and human expression pattern could still be 
inferred, for instance high level expression of Klf5 was ob-
served in the skeletal muscle in humans, while its expression 
was very weak in the case of mice. We have also looked at 
its expression in the human skin and found that it is highly 
expressed in the epidermis especially in cells of the inner 
root sheath and matrix of the hair follicles [10]. 
2. ROLE IN PROLIFERATION 
  From the expression pattern of Klf4 and Klf5 it was in-
ferred that Klf5, being expressed in the proliferative com-
partment of both the skin and intestine might function as a 
pro-proliferative factor while Klf4 which is expressed in the 
differentiating compartment has growth inhibitory functions. 
Results from several laboratories have corroborated this idea. 
In one of the earliest reports on Klf4, transfection of Klf4 
into NIH3T3 fibroblasts, inhibited their DNA synthesis. Fur-
ther, its expression was induced in growth inhibitory condi-
tions like serum starvation and contact inhibition [5]. Subse-
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demonstrated in additional settings. For instance, it inhibits 
the proliferation of vascular smooth muscle cells via the in-
duction of p53 [11]. In B-cells, Klf4 regulates cell number 
and activation-induced B-cell proliferation [12, 13]. Stimula-
tion of proliferation of mature B-cells from mouse spleen 
with anti-IgM antibodies in vitro resulted in a rapid down-
regulation of Klf4. As expected, the forced expression of 
Klf4 in proliferating B-cells caused an arrest or delay in cell 
cycle progression. These cells consistently had an increased 
percentage of cells in the G1 phase of the cell cycle and a 
decreased percentage in the S phase [12]. Thus Klf4 acts as a 
quiescent factor for B cells. A similar function has been at-
tributed to Klf4 in T-cells [14]. Ectopic expression of Klf4 in 
pancreatic cancer lines also leads to cell cycle arrest and 
marked growth inhibition in vitro [15]. It has been further 
shown that Klf4 can inhibit cell proliferation by blocking the 
G1/S progression of the cell cycle [16] and that Klf4 can 
directly repress CyclinD1 promoter [17]. 
  Klf5 on the other hand is pro-proliferative in several set-
tings. Constitutive expression of Klf5 in NIH3T3 cells 
causes accelerated cell growth [18]. Further, these cells ex-
hibit serum and anchorage independent growth. In this study, 
overexpression of Klf5 was sufficient to cause a transformed 
phenotype as assessed by focus formation and loss of contact 
inhibition. The pro-proliferative effect of Klf5 in non-
transformed cell lines from the intestine and skin has also 
been demonstrated [19-21]. Additionally, the growth inhibi-
tion of IEC6 (a non transformed intestinal epithelial cell line) 
by all-trans retinoic acid (ATRA) can be overcome via Klf5 
overexpression [22]. This corresponds well with the down-
regulation of Klf5 seen upon ATRA treatment in this cell 
line.  
  Although, as described above, Klf4 functions as a growth 
inhibitor and Klf5 as a pro-proliferative factor, both factors 
surprisingly exhibit context dependent effects. For Klf4, it is 
best exemplified by the study of Rowland et al. [23], in 
which Klf4 overexpression in wildtype mouse embryonic 
fibroblasts (MEFs) resulted in a tight proliferative arrest 
within 2 days. In contrast, in MEFs carrying an oncogenic 
RAS
v12, Klf4 overexpression bypassed the Ras
v12 induced 
senescence. Its expression in these cells led to cellular prolif-
eration, loss of contact inhibition, an ability to grow in an 
anchorage-independent manner and resistance to cisplatin (a 
commonly used anti-cancer drug)-induced apoptosis. 
Mechanistically, Klf4 simultaneously repressed p53 (which 
promotes cell proliferation) and induced p21
cip1 (which in-
hibits cell proliferation) expression. In normal cells, the 
p21
cip1 induction by Klf4 represents the dominant response, 
resulting in cell-cycle arrest. In Ras
v12 expressing cells, the 
increased cyclin-D1 levels neutralize the p21
cip1 function. 
This leaves the inhibition of p53 by Klf4 as the dominant 
function, thereby, promoting cell proliferation and/or cell 
survival. Thus Klf4 although acting as an inhibitor of prolif-
eration in many settings, possesses a pro-mitogenic activity 
that is uncovered only within a specific genetic context. At 
this point it is not clear how Klf4 simultaneously activates 
the p21 promoter and represses the p53 promoter. When it 
comes to Klf5, the scenario is a bit more clearer.  
  Similar to Klf4, Klf5 also shows context dependent roles. 
Although it is known to promote proliferation it can also be 
anti-proliferative. For instance, in primary intestinal cells, 
overexpression of Klf5 generally leads to an increased pro-
liferation. Its overexpression in transformed cells however, 
causes growth arrest [19]. A similar outcome has been ob-
served upon overexpression of Klf5 in several cell lines [24-
27]. The context dependent function of Klf5 in regulating 
proliferation is further illustrated by the observation that 
Klf5 was required for proliferation of the spontaneously im-
mortalized keratinocyte cell line HaCat. Surprisingly, it was 
also required for TGF-mediated growth inhibition. In this 
study, knockdown of Klf5 in HaCat cells resulted in an inhi-
bition of cell proliferation. Although these cells exhibited 
reduced proliferation compared to the control, they failed to 
undergo growth inhibition upon TGF stimulation [21]. The 
authors further showed that acetylation of Klf5 is responsible 
for the TGF-mediated functional reversal of Klf5. The 
TGF-mediated acetylation of Klf5 altered its protein inter-
actions and promoter binding, thereby, switching it from a 
transcriptional activator to a repressor on the p15(CDKN2B) 
promoter [26]. 
3. ROLE IN DIFFERENTIATION 
  Several mouse models have been generated which either 
lack the expression or ectopically express these factors. 
These models have clearly defined the roles of Klf4 and 
Klf5, not only in regulation of proliferation but also in regu-
lating differentiation programmes of cells. A summary of 
phenotypes arising due to alterations in the Klf4 or Klf5 ac-
tivity in mice is provided in Fig. (1). 
3.1. Klf4 
  Knockout (KO) of Klf4 in mice results in neonatal lethal-
ity [7]. The Klf4
-/- mice were born at the expected mendelian 
ratio and were initially indistinguishable from their litter-
mates but died within 15 hrs of birth. Further examination 
revealed that the neonatal lethality was due to a defective 
skin barrier formation resulting in rapid dehydration and 
death. The importance of Klf4 in generating the skin barrier 
was further demonstrated in a reciprocal experiment where 
ectopic expression of Klf4 in the basal layer, via the keratin5 
promoter resulted in an accelerated barrier acquisition [28]. 
While in control mice the barrier formation initiates at E16.5 
and is fully established by E17.5 during development, the 
K5-Klf4 bitransgenic animals had almost completely estab-
lished the barrier by E16.5. At both E16.5 and E17.5, these 
mice also exhibited an approx 40% decrease in proliferation 
in the skin. The differentiation pattern was not altered. Inter-
estingly, the Klf4-mediated acceleration of skin barrier for-
mation is similar to the increased barrier acquisition in hu-
man fetus upon antenatal administration of corticosterone. 
Transcriptional profiling of dorsal skin from Klf4
-/-, K5-Klf4 
and Dexamethasone (a corticosteroid)-treated mice further 
showed that Klf4 and corticosteroids target overlapping set 
of genes [29]. 
  In another study, postnatal overexpression of Klf4 in the 
basal layer of the epidermis via the Keratin14 promoter led 
to rapid development of hyperkeratosis, atrophy of the seba-
ceous glands, cystic degeneration of hair follicles and hyper-
plasia [30]. These changes developed by 9 days of transgene 
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dysplastic changes in the skin by 3-4 weeks of induction. 
These dysplastic changes progressed into SCC in situ. The 
Klf4-induced dysplasia could be promoted by p53 deficiency 
and the authors further showed that the transforming ability 
of Klf4 required its nuclear translocation. At present a direct 
comparison of K5-Klf4 and K14-rtTA;TRE-Klf4 mouse mod-
els is not available. Since Jaubert et al. [28] used the mouse 
allele while Foster et al. [30] used the human allele of Klf4, 
it would be interesting to determine if there are any species-
specific differences.  
  Klf4 deficiency also results in abnormalities in the colon. 
Since the Klf4
-/- animals die within 15 hours of birth, these 
animals were examined on postnatal day1, the latest stage of 
intestinal differentiation before death [31]. Although the cell 
proliferation and cell death rates were normal in these ani-
mals, the colonic mucosa appeared abnormal and there was a 
dramatic reduction of mature goblet cells (by 90%). These 
are specialized epithelial cells that protect the intestinal mu-
cosa from injury and help in repair. The colonocytes and 
enteroendocrine cells, the other specialized cells of the colon 
were not altered. Loss of goblet cells is also observed in 
mice with a conditional deletion of Klf4 in the eye via Le-
Cre mediated recombination [32]. While at postnatal day 1 
Le-Cre/Klf4 
loxP/loxP mice look normal, by 8 weeks they de-
velop multiple ocular defects, including corneal epithelial 
fragility, stromal edema, defective lens and loss of conjunc-
tival goblet cells. Interestingly, the reduced number of 
epithelial cell layers observed in these mice was not due to 
reduced rate of cell proliferation but rather due to increased 
sloughing/fragility of the epithelium. In order to obtain 
mechanistic insight into the diverse ocular surface phenotype 
of these mice, the group further compared the gene expres-
sion patterns between the WT and Le-Cre/Klf4 
loxP/loxP mice 
and found that Klf4 contributes to corneal homeostasis by 
coordinately regulating the expression of subsets of genes 
involved in specific functions such as cell cycle progression, 
cell-cell adhesion, epithelial barrier formation, expression of 
corneal crystallins and maintenance of corneal hydration 
[33]. 
  Conditional ablation of Klf4 in the stomach via  
Foxa3-Cre results in gastric hypertrophy and mucus cell hy-
perplasia, starting at 2 weeks of age. The Foxa3-
Cre/Klf4
loxP/loxP mice had a 4-fold increased proliferation by 
6 months of age. The adult gastric unit consists of at least 5 
different mature cell types: the pit or surface mucous cells, 
which produce mucins and other factors involved in mucosal 
protection; the parietal or oxyntic cells, which secrete acid; 
the zymogenic or chief cells, which secrete pepsin; the en-
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teroendocrine cells, which provide a number of gastric hor-
mones including gastrin; and the caveolated or brush cells. 
Klf4 deletion resulted in a 2-fold increase in the number of 
pit cells and a 4-fold increase in the number of mucus neck 
cells. The number of parietal and zymogenic cells on the 
other hand was reduced to half. The enteroendocrine cells 
per gland and the apoptotic rate was not altered. From this 
study, it was concluded that Klf4 is required for directing the 
cell-fate decisions of the gastric epithelial precursor cells 
[34]. 
  Conditional ablation of Klf4 in Sertoli cells of the testis 
did not affect proliferation. In the AMH-Cre/Klf4
loxP/loxP mu-
tant mice, the seminiferous tubules exhibited a disorganised 
germinal epithelium. Amongst the genes whose expression 
was altered in these mice, the authors found a number of 
genes involved in the maintenance of the differentiation 
function and/or directed vesicle transport in polarized epithe-
lial cells [35].  
  Klf4 is also expressed in a monocyte-restricted and stage-
specific pattern during myelopoiesis and functions to pro-
mote monocyte differentiation [36]. Hematopoetic stem cells 
(HSCs) generate committed progenitor cells that loose the 
capacity to self renew and ultimately differentiate along a 
specific lineage to form mature blood cells. In the myeloid 
pathway, mature monocytes and granulocytes arise from 
bipotential granulocyte/macrophage progenitors (GMPs) 
that, in turn, arise from multipotential common myeloid pro-
genitors (CMPs); CMPs may also give rise to bipotential 
megakaryocyte/erythrocyte progenitors (MEPs). Overex-
pression of Klf4 in promyelocytic HL-60 cells or in primary 
CMPs or HSCs from bone marrow, restricts these cells along 
the monocyte/macrophage lineage at the expense of other 
myeloid lineages and confers the morphologic, genetic, and 
functional characteristics of a mature monocyte. Recipro-
cally CMPs derived from wildtype or Klf4
loxP/loxP mice were 
retrovirally transfected with Cre recombinase and subse-
quently grown in medium capable of differentiating the cells 
along all myeloid pathways. CMPs with Klf4 deletion 
showed marked reduction of upto 56% in the formation of 
mature monocytes, whereas granulocyte formation was in-
creased by 36%. Similarly Cre-excision of Klf4 in HSCs 
from Klf4
loxP/loxP resulted in a 40% reduction in the number 
of monocytes and a 41% increase in granulocyte formation. 
These results thus show that varying amounts of Klf4 may 
dynamically regulate the balance between monocytes and 
granulocytes. 
3.2. Klf5 
  Mice lacking Klf5 die during embryogenesis [37, 38]. 
The heterozygous mice survive and their analysis has de-
fined several functions of Klf5. The Klf5
+/- mice show re-
duced responses to injury and angiogenesis [37]. In response 
to external stress these mice had diminished arterial wall 
thickening, angiogenesis, cardiac hypertrophy and interstitial 
fibrosis. The activation and proliferation of smooth muscle 
cells and fibroblasts in response to vascular injury was im-
paired. In this model, Klf5 was identified as one of the tran-
scription factors mediating Angiotensin II induced cardio-
vascular remodeling which could explain parts of the ob-
served phenotype. It was also shown that Klf5 increased the 
expressions of platelet-derived growth factor-A (PDGF-A) 
and TGF- during vascular remodeling and that this activity 
of Klf5 could be modulated by retinoic-acid receptor (RAR) 
ligands.  
 The  Klf5
+/-  mice also exhibit defects in adipocyte 
differentiation [39]. The neonatal Klf5
+/- mice have reduced 
mass of white adipose tissue (WAT). There was no 
difference in the number of adipocytes between the Klf5
+/- 
and wildtype mice. However, a number of cells were small 
and contained little or no lipid droplets which normally are 
produced upon adipocyte differentiation. Although clearly 
reduced in neonates, by 4 weeks of age the WAT mass and 
morphology was comparable to the wild type. The 
development of brown adipose tissue (BAT) was not 
affected. In the in vitro model of adipocyte differentiation, 
introduction of a dominant negative Klf5 construct into the 
preadipocytes 3T3-L1 cells resulted in an almost complete 
block of the formation of lipid droplets. Conversely 
overexpression of Klf5 in these cells led to their spontaneous 
differentiation in confluent cultures. Mechanistically, Klf5 
acted in concert with C/EBP and  to activate the PPAR2 
promoter that in turn controls a number of adipocyte-specific 
genes. The Klf5
+/- mice also have skeletal growth retardation 
in the perinatal period. Although chondrocyte proliferation 
and differentiation were normal, cartilage matrix degradation 
was impaired in these mice causing a delay in replacement of 
cartilage with bone at the primary ossification center in the 
embryonic limbs. This defect was attributed to the effect of 
Klf5 on matrix metalloproteinase 9 (MMP9) expression 
which is required for matrix degradation, calcification and 
vascularization of the skeleton [40].  
 Although  the  Klf5
+/- mouse model clearly demonstrates 
the effects of Klf5 on non-epithelial cells, a detailed his-
tological picture of the effect of Klf5 deletion on the colon/ 
skin epithelial cells is currently not available. We have over-
expressed Klf5 in the basal layer of the epidermis and found 
that its overexpression leads to loss of proliferation and 
misexpression of differentiation markers in the epidermis 
during development [41]. The overexpression of Klf5 also 
results in the disruption of epithelial-mesenchymal crosstalk 
causing defects in the underlying skeleton. This is quite 
striking since the overexpression of Klf5 is restricted only to 
the epidermis. When we induced Klf5 expression in adult 
mice, localized proliferation and epidermal erosions were 
observed. This phenotype was associated with a loss of the 
stem cells of the hair follicle bulge. These results demon-
strate that 1) Klf5 can regulate differentiation states of the 
keratinocyte and 2) its effect on proliferation in the epider-
mis is context-dependent. Additionally even though the dif-
ferentiation pattern was altered in this model, Klf5 overex-
pression did not lead to expansion of any one particular line-
age. Based on these data we proposed a model wherein Klf5 
expression is detrimental for cells capable of lineage com-
mitment while it might be pro-proliferative in lineage com-
mitted cells of the epidermis. This idea is presently under 
investigation. It would be very interesting to determine as to 
what will be the outcome of Klf5 deficiency in the epider-
mis. Although the Keratin5 promoter is also expressed in the 
esophagus resulting in Klf5 overexpression there as well, we 
did not detect any gross abnormalities. This is consistent 
with results of Goldstein et al. [42] who have overexpressed 598    Current Genomics, 2009, Vol. 10, No. 8  Inderpreet Sur 
Klf5 throughout the esophageal epithelia via  the Epstein-
Barr virus (EBV) ED-L2 promoter. They however, did ob-
serve increased proliferation in the basal layer. The number 
of proliferating cells was increased two-fold at both 1 mo 
and 1 yr of age. However, the suprabasal layers undergoing 
differentiation did not show increased proliferation despite 
the ectopic expression of Klf5.  
 Recently  Klf5
loxP/loxP mice have been generated which 
allows for conditional deletion of Klf5 in various tissues 
[43]. So far these mice have been bred into (TetO)7-Cre
-/tg 
and SFTPC-rtTA
-/tg mouse strains. In these mice, Klf5 was 
deleted in the respiratory epithelial cells of the triple trans-
genic mice upon doxycycline treatment [43]. Deletion of 
Klf5 during embryonic lung development resulted in the 
death of Klf5
/  mice shortly after birth due to respiratory 
distress. The authors found no effect of Klf5 deletion on pro-
liferation of pulmonary epithelial or mesenchymal cells in 
the lungs of E15.5 embryos. Instead, the deletion of Klf5 in 
the respiratory epithelial cells inhibited morphological and 
biological maturation of the lung. Klf5 was found to regulate 
the maturation of both typeI and typeII epithelial cells. Klf5 
deficiency in the respiratory epithelium also altered the un-
derlying mesenchyme. Expression of SMA, a marker of 
bronchiolar and vascular smooth muscle cell differentiation, 
was markedly increased in the bronchioles of the lungs from 
Klf5
/ mice. Additionally the normal association of epithe-
lial and endothelial cells was disrupted. Microarray analysis 
identified alterations in several genes linked to paracrine 
signaling  via  TGF, PDGF, Vascular endothelial growth 
factor (VEGF) and Fibroblast growth factors (FGF). 
4. ROLE IN STEM CELLS 
  Apart from the proliferation and differentiation functions 
of Klf4 and Klf5 discussed in the preceding sections, the 
most striking role for this family was recently demonstrated 
when it was found that Klf4 together with additional factors 
(Oct4, Sox2 and c-Myc) has the capacity to reprogram fetal 
as well as adult fibroblasts into pluripotent embryonic stem 
cells [44-47]. Further it has been established that a core Klf 
circuitry of Klf2, Klf4 and Klf5 regulates self-renewal of 
embryonic stem cells (ESC) [48]. This is the best evidence to 
date that Klf4 and Klf5 can perform similar function. This 
could also explain why Klf4
-/- mice are viable but die soon 
after birth due to barrier defects. Other family members 
might compensate for Klf4 loss during development. Klf5 on 
the other hand appears to be indispensable for derivation of 
ESC from inner cell mass (ICM) of the mouse embryo [38]. 
In this study Ema et al. showed that Knockout (KO) of Klf5 
resulted in an implantation defect of the embryos due to their 
inability in generating a functional trophoectoderm. They 
further showed, in an outgrowth assay, that the majority of 
Klf5
-/- blastocysts failed to attach to the dish and ESCs could 
not be derived from Klf5
-/- inner cell mass. The group instead 
established the Klf5
-/- ESC cell lines by replacing the wt al-
lele in the Klf5
+/- E S C  w i t h  a n  I R E S - h y g
r cassette. Early 
passage Klf5
-/- ESCs, appeared normal but later passage cells 
exhibited a differentiated morphology. Although these cells 
maintain pluripotency at the molecular level as determined 
by the unaltered expression of Oct3/4, Rex1 and Nanog, the 
differentiation markers like Fgf5, Brachyury and Cdx2 were 
increased in Klf5
-/- ESCs. These cells when provided with an  
environment permissive for differentiation could differenti-
ate earlier than the wildtype cells. Thus KO of Klf5 results in 
priming of these cells for differentiation. In this regard it is 
significant that triple knockout of Klf2, Klf4 and Klf5 results 
in a gene expression signature which is similar to EpiSC, a 
pluripotent cell line derived from the epiblasts [48]. The 
EpiSC are pluripotent, but their pluripotency is more re-
stricted than that of embryonic stem cells. Interestingly, the 
differentiation defect of Klf5
-/- ESCs can be compensated by 
Klf4. On the other hand Klf5
-/- ESCs also have a defect in 
proliferation which cannot be compensated by Klf4 [38]. 
These data suggest that the proliferation and differentiation 
are independent functional arms of Klf5. It also needs to be 
mentioned that contrary to the above results, Jiang et al. [48] 
in their study did not find any significant self renewal defects 
due to knockdown of Klf5 suggesting that a complete 
knockout of Klf5 is required.  
  Although Klf5 is essential for pluripotency, it is down-
regulated in several adult stem cells. As discussed before, in 
the epidermis Klf5 is expressed in the basal layer that con-
tains the proliferating compartment while Klf4 is expressed 
in the suprabasal layer and regulates the expression of genes 
required for the formation of the barrier. The hair follicle 
contains a stem cell niche defined by the bulge region. Tran-
scriptional profiling of the bulge cells isolated by the Krt1-
15 expression and their comparison to the non-bulge basal 
keratinocytes showed that Klf5 was downregulated (five 
fold) in the stem cell compartment [49]. Similar results were 
obtained in transgenic mice expressing Tcf3 [50]. Tcf3 gov-
erns stem cell features and represses cell fate determination 
in the skin. Klf5 was downregulated in the developing epi-
dermis at time points correlating with Tcf3 expression. Fur-
ther, overexpression of Tcf3 in the epidermis led to an ex-
pression of the bulge stem cell transcriptional profile. This 
expression profile was also associated with a downregulation 
of Klf5. Finally it was shown that Tcf3 actively bound the 
Klf5 promoter in this study. Klf5 is also downregulated in 
Lgr5+ stem cells of the hair follicle [51]. The Lgr5+ cells 
constitute an actively cycling stem cell population of the hair 
follicle. The data from both the Lgr5 and Tcf3 study further 
suggests that the downregulation of Klf5 in the adult stem 
cells of the hair follicle is not linked to quiescence. Addi-
tionally Klf5 downregulation in these cells does not appear 
to be linked to stemness per se since hair germ cells that 
arise from the bulge cells show increased expression of Klf5 
inspite of retaining several but not all features of stemness 
[52]. 
  The downregulation of Klf5 observed in adult epidermal 
stem cells is not limited to the epidermis alone. A genetic 
and functional comparison of neural stem cells and embry-
onic stem cells showed a downregulation of Klf5 in the neu-
ral stem cells. In this study, Klf4 was also downregulated but 
to a more modest extent [53]. Thus from these data it appears 
that Klf4/ Klf5 might function more as factors whose pres-
ence or absence restricts fates. Since Klf4 and Klf5 are tran-
scription factors that can bind DNA and alter target gene 
expression, it is possible that by regulating the assembly of 
signal-induced transcription factors on specific sites on the 
genome, they might influence diverse fates.  
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5. TRANSCRIPTIONAL REGULATION 
  Although in Drosophila, Krüppel functions primarily as a 
transcriptional repressor, in mammals, Krüppel-like factors 
can function as transcriptional activators or as transcriptional 
repressors. Several stimuli are known to activate Klf4 [54-
63] and Klf5 [20, 22, 64-71]. The activation of these factors 
regulate a variety of target genes belonging to diverse cellu-
lar processes [72, 73]. How these proteins accomplish such 
diverse functions or how the specificity is generated is still 
an open question. Protein modifications which may alter not 
only their transactivation functions but also their interactions 
with other proteins are likely to play a major role. These fac-
tors are known to be ubiquitinated [74-77], phosphorylated 
[78], acetylated [21, 26, 79, 80] and SUMOylated [81-83]. 
How protein modifications alter their function is best exem-
plified by the observation that SUMOylation functions as a 
molecular switch in converting Klf5 from a repressor to a 
transactivator in transcriptional programs of lipid metabo-
lism involving Peroxisome proliferator-activated receptor- 
(PPAR-) [82]. In this study, it was elegantly shown that 
Klf5 modified with small ubiquitin-related modifier (SUMO) 
proteins was associated with transcriptionally repressive 
regulatory complexes containing unliganded PPAR- and 
co-repressors NCor, SMRT. In this state, Klf5 inhibited the 
expression of Cpt1b, Ucp2 and Ucp3 which are genes in-
volved in lipid oxidation and energy uncoupling. Upon ago-
nist stimulation of PPAR-, Klf5 was deSUMOylated and 
became associated with transcriptional activation complexes 
containing both the liganded PPAR- and CREB binding 
protein (CBP). Similar to the effect of SUMOylation de-
scribed above, acetylation of Klf5 can also reverse its func-
tion [21, 26]. It was shown that knockdown of Klf5 in HaCat 
cells significantly repressed cell proliferation. However 
knockdown of Klf5 also blocked the TGF- induced growth 
inhibition. Reciprocally, overexpression of Klf5 resulted in 
increased proliferation but also sensitized cells to TGF- 
mediated growth inhibition. Thus Klf5 was converted from a 
pro-proliferative factor into an anti-proliferative factor upon 
TGF- signaling. Mechanistically acetylation of Klf5 altered 
its binding to the p15 (CDKN2B) promoter, a bona fide tar-
get of TGF-. Thus this study also reinforces the idea that 
protein modification of Klf5 can alter its function. It also 
highlights another level of complexity. In contrast to the ef-
fect of SUMOylation, acetylation appears to primarily affect 
the DNA-binding ability of Klf5. Additionally, these effects 
are likely to be promoter-specific since a previous study re-
ported that the acetylation state of Klf5 does not alter its 
binding to the Klf5 binding sequence in EMSA [80].  
  Similar to Klf5, the Klf4 protein is also acetylated on 
residues Lys-225 and Lysine-229 by p300. The acetylation 
sites were required for the induction of the endogenous 
p21
cip1/waf1 and Intestinal alkaline phosphatase (IAP) as well 
as for inhibition of proliferation [79]. However, mutation of 
the acetylation site did not affect the repressive function of 
Klf4 on the CyclinB1 promoter in the same study. 
6. ROLE IN TUMOUR DEVELOPMENT 
  Given that Klf4 and Klf5 have context dependent roles, it 
is not surprising that Klf4 and Klf5 possess both tumor sup-
pressor and oncogenic functions. Klf4 is downregulated in 
many human cancers including colorectal [84], gastric [85, 
86], bladder [87] and adult T cell leukemia [88]. In the pan-
creatic cancer cell lines, the Klf4 expression is associated 
with increased doubling time i.e. slower growth [15]. Klf4 is 
also downregulated in several types of B-lineage lymphomas 
and leukemias relative to normal tissue. Overexpression of 
Klf4 also suppressed the transformation of pre-B cells by 
ABL oncogenes [89]. Although these observations clearly 
define Klf4 as a tumor suppressor, it can also function as an 
oncogene. Schoenhals et al. [90] in their attempt to deter-
mine the expression of the embryonic stem cell markers in 
cancers, found an association of Klf4 overexpression with 
acute lymphoblastic leukemia, hairy cell leukemia and mul-
tiple myeloma. Additionally, Klf4 is overexpressed in oral 
squamous cell carcinoma and primary ductal carcinomas of 
the breast [30, 91].  
  The complexity does not end here since Klf4 can func-
tion either as an oncogene or tumor suppressor in the same 
tumor type. For instance, in vitro experiments using Estrogen 
receptor (ER)  positive breast cancer cell line MCF7 have 
revealed that estrogen dependent cell-growth was signifi-
cantly enhanced by knockdown of Klf4 [92]. This would be 
consistent with the growth inhibitory function of Klf4. Ear-
lier studies have however shown that 70% of breast cancers 
have elevated expression of Klf4 and that increased nuclear 
staining of Klf4 is associated with a more aggressive pheno-
type [91]. The inconsistencies between the two studies might 
reflect alterations in genetic context.  
  Mouse models have further highlighted the tumour sup-
pressor versus oncogenic function of Klf4. Haploinsuffi-
ciency of Klf4 promotes adenomatous polyposis coli (APC)-
dependent intestinal tumorigenesis [93]. In this study the 
Apc
Min/+ mouse model which is a well established model of 
intestinal tumorigenesis was used. The tumor burden in 
Klf4
+/-/Apc
Min/+ mice was significantly increased compared to 
the  Apc
Min/+ mice. In the skin however, overexpression of 
Klf4 resulted in the development of squamous cell carci-
noma [30].  
  Klf5 can also function as either a tumour suppressor or 
an oncogene. Its expression is downregulated in several hu-
man cancers including those of the breast [24], prostate [80] 
and esophagus [27]. Moreover, the degradation of Klf5 was 
enhanced in cancer cell lines from breast and prostate as 
compared to the non-neoplastic cells [76]. It was also shown 
that Klf5 overexpression in non-transformed intestinal cell 
lines promoted their growth while Klf5 overexpression in 
transformed cell lines led to growth inhibition. Further Ras-
mediated transformation of intestinal epithelial cells led to 
altered growth related properties of Klf5 [19]. Namely, Klf5 
overexpression inhibited growth of Ras-transformed intesti-
nal epithelial cells. Although these results are consistent with 
the observations made in breast [24], prostate [25] and eso-
phageal [27] cancer cell lines, data contradicting a Klf5 
growth inhibitory role in transformed cells is also available 
[20]. 
  Regarding the oncogenic potential of Klf5, it has been 
shown to mediate the transforming activity of oncogenic H-
Ras in NIH-3T3 cells [94]. Klf5 is highly expressed in hu-
man primary colorectal cancers exhibiting K-Ras mutations 
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[95]. Furthermore, Klf5 expression has been suggested as a 
prognostic factor for overall survival in patients with spo-
radic breast cancer, with higher Klf5 expression correlating 
with shorter disease free survival and poorer overall survival 
[96]. Klf5 also promotes cell proliferation and tumorigenesis 
of the TSU-Pr1 human bladder cancer cell line [97] and Klf5 
overexpression may be linked to salivary gland tumors [98]. 
Further in the mouse model of intestinal tumorigenesis, hap-
loinsufficiency of KLF5 rescues the tumor initiating effect of 
the Apc
Min mutation in the intestine [99].  
7. UNITY IN DIVERSITY 
  As discussed, Klf4 and Klf5 control diverse functions in 
which they might antagonize or co-operate with each other. 
The data generated from the available mouse models shows 
that the consequence of Klf4 or Klf5 alteration is very often 
a change in lineage commitment/ differentiation programmes 
(discussed in section 3). It is possible that the diverse func-
tions of Klf4 and Klf5 reflect their main function as 
´priming-factors` or ´Fate-keepers` for signal induced differ-
entiation/ lineage commitment. It is tempting to speculate 
that a sinusoidal wave of expression of these factors along 
the axis of lineage hierarchy may determine the sequential 
appearance of different cell types. This idea is represented in 
Fig. (2). In this regard it is noteworthy that Klf5 expression 
is high in the ESC but downregulated in pluripotent cell-
lines generated from the epiblast of mouse embryos (EpiSC) 
[48]. The EpiSC have a more restricted pluripotency than 
embryonic stem cells. Further, Klf5 is also downregulated in 
the adult bulge hair follicle stem cells. This downregulation 
is however not associated with quiescence (see section 4). 
Interestingly, although Klf5 is downregulated in the bulge 
stem cells of the hair follicles, its expression goes up in the 
hair germ cells. The latter defines a cluster of cells in the hair 
follicle in a transitional state between the bulge stem cells 
and the matrix transit amplifying cells with a high prolifera-
tive potential [52]. These observations would be consistent 
with the model depicted in Fig. (2). How can Klf4/5 accom-
plish such a task? Unlike several transcription factors that are 
tightly coupled to specific signaling pathways like Gli or 
smads, Klf4 and Klf5 are not restricted to a single signaling 
pathway. It is possible that these factors are functioning as 
flagposts on the genome, priming it for signal-mediated acti-
vation and lineage commitment. ChIP on ChIP experiments 
would go far in addressing this issue. Future experiments 
elucidating the molecular mechanisms behind Klf4/5 func-
tions will be instrumental in determining the validity of this 
model. 
8. CONCLUDING REMARKS 
  Regenerative medicine has become very attractive since 
the observation that it is possible to generate patient specific 
iPS cells. An understanding of the basic mechanisms as to 
how cell fates are regulated is expected to provide novel 
means of manipulating this process. The therapeutic poten-
tials of such a manipulation are far reaching. In this regard, 
Klf family members provide an excellent target for investi-
gation.  
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